Drug Trial Radar · NCT05411081
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Mar 24, 2023
Primary completion
Jul 1, 2027
Study completion Jul 1, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jun 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread from where it first started (primary site) to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and waste as urine. Most papillary tumors look like long, thin finger-like growths under a microscope. It is also called papillary kidney cancer or PRCC. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the tumor and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of tumor cells. Combination therapy with atezolizumab and cabozantinib may shrink the tumor and allow a longer survival time in patients with metastatic renal cell carcinoma.
Conditions
- Metastatic Papillary Renal Cell Carcinoma
- Stage IV Renal Cell Cancer AJCC v8
Interventions
AtezolizumabBiological
Given IV
Biospecimen CollectionProcedure
Undergo collection of blood and urine samples
Bone ScanProcedure
Undergo bone scans
Cabozantinib S-malateDrug
Given PO
Computed TomographyProcedure
Undergo CT scans
Magnetic Resonance ImagingProcedure
Undergo MRI
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survivalTime frame: From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 5 years
Locations
198 sites in 1 country. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona
Cancer Center at Saint Joseph's
Phoenix, Arizona
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Kaiser Permanente-Anaheim
Anaheim, California
Kaiser Permanente-Baldwin Park
Baldwin Park, California
Kaiser Permanente-Bellflower
Bellflower, California
City of Hope Comprehensive Cancer Center
Duarte, California
Epic Care-Dublin
Dublin, California
Epic Care Partners in Cancer Care
Emeryville, California
Kaiser Permanente-Fontana
Fontana, California
Kaiser Permanente South Bay
Harbor City, California
Kaiser Permanente-Irvine
Irvine, California
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
Kaiser Permanente West Los Angeles
Los Angeles, California
Contra Costa Regional Medical Center
Martinez, California
Kaiser Permanente-Ontario
Ontario, California
Kaiser Permanente - Panorama City
Panorama City, California
Kaiser Permanente-Riverside
Riverside, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
Kaiser Permanente-San Diego Zion
San Diego, California
Kaiser Permanente-San Marcos
San Marcos, California
Epic Care Cyberknife Center
Walnut Creek, California
Kaiser Permanente-Woodland Hills
Woodland Hills, California
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho
Saint Luke's Cancer Institute - Boise
Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho
Saint Luke's Cancer Institute - Fruitland
Fruitland, Idaho
Saint Luke's Cancer Institute - Meridian
Meridian, Idaho
Saint Alphonsus Cancer Care Center-Nampa
Nampa, Idaho
Saint Luke's Cancer Institute - Nampa
Nampa, Idaho
Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, Idaho
Saint Luke's Cancer Institute - Twin Falls
Twin Falls, Idaho
Illinois CancerCare-Bloomington
Bloomington, Illinois
Illinois CancerCare-Canton
Canton, Illinois
Illinois CancerCare-Carthage
Carthage, Illinois
Northwestern University
Chicago, Illinois
Carle at The Riverfront
Danville, Illinois
Showing 40 of 198 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.